Nasus Pharma founder holds 1,888,873 shares

Nasus Pharma Ltd director, Chief Development Officer and founder Dr. Dalia Megiddo filed an initial statement of beneficial ownership of securities.

Accepted by SEC EDGAR 03/27/2026 - 08:56 PM EDT

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Nasus Pharma Ltd director, Chief Development Officer and founder Dr. Dalia Megiddo filed an initial statement of beneficial ownership of securities. She reports beneficial ownership of 1,888,873 Ordinary Shares held directly.

She also reports indirect beneficial ownership of 5,195 Ordinary Shares held by Formulex Pharma Innovations Ltd, where she is a beneficial owner and may be deemed to beneficially own those shares as well. The filing does not reflect any recent share purchases or sales, only current holdings.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Megiddo Dalia

Role Chief Development Officer

Type	Security	Shares	Price	Value
Holding	Ordinary Shares	--	--	--
Holding	Ordinary Shares	--	--	--

Holdings: Ordinary Shares — 1,888,873 shares (Direct); Ordinary Shares — 5,195 shares (Indirect, By Formulex Pharma Innovations Ltd.)

Footnotes (1)

F1. Represents ordinary shares of the Issuer, no par value ("Ordinary Shares") directly held by Formulex Pharma Innovations Ltd. ("Formulex"). Dr. Dalia Megiddo, as a beneficial owner of Formulex, may be deemed to beneficially own the Ordinary Shares owned directly by Formulex.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Nasus Pharma (NSRX) disclose in Dr. Dalia Megiddo’s Form 3?

Nasus Pharma’s Form 3 shows Dr. Dalia Megiddo’s existing shareholdings. She reports 1,888,873 Ordinary Shares held directly and 5,195 Ordinary Shares held indirectly through Formulex Pharma Innovations Ltd, providing a snapshot of her ownership when she became a reporting insider.

How many Nasus Pharma (NSRX) shares does Dr. Dalia Megiddo hold directly?

Dr. Dalia Megiddo directly holds 1,888,873 Ordinary Shares of Nasus Pharma. This direct position reflects her personal ownership as reported in the Form 3 and establishes her stake as a director, officer, and founder of the company.

What is the indirect Nasus Pharma (NSRX) ownership reported via Formulex?

The filing reports 5,195 Ordinary Shares held indirectly via Formulex Pharma Innovations Ltd. As a beneficial owner of Formulex, Dr. Dalia Megiddo may be deemed to beneficially own these shares in addition to her directly held position.

Does the Nasus Pharma (NSRX) Form 3 show any recent insider buying or selling?

No recent insider purchases or sales are indicated in this Form 3. The entries are classified as holdings, meaning the document records Dr. Dalia Megiddo’s existing ownership stakes rather than reporting new transactions in Nasus Pharma shares.

What roles does Dr. Dalia Megiddo hold at Nasus Pharma (NSRX)?

Dr. Dalia Megiddo is a director, Chief Development Officer, and founder of Nasus Pharma. Her multiple leadership roles, combined with significant share ownership, align her interests closely with the company’s long-term performance and strategic direction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Megiddo Dalia

(Last)

(First)

(Middle)

P.O. BOX 284

(Street)

TEL-AVIV-YAFO

6100201

(City)

(State)

(Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Nasus Pharma Ltd [ NSRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)	X	Other (specify below)
	Chief Development Officer		Founder

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	1,888,873	D
Ordinary Shares	5,195	I	By Formulex Pharma Innovations Ltd.⁽¹⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)

Explanation of Responses:

1. Represents ordinary shares of the Issuer, no par value ("Ordinary Shares") directly held by Formulex Pharma Innovations Ltd. ("Formulex"). Dr. Dalia Megiddo, as a beneficial owner of Formulex, may be deemed to beneficially own the Ordinary Shares owned directly by Formulex.

	/s/ Dalia Megiddo	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR